

PRODUCT INFORMATION

| | |
|---|--|
| Clone ID | DMC467 |
| Target | TGFBR2 |
| Synonyms | AAT3; FAA3; LDS1B; LDS2; LDS2B; MFS2; RIIC; TAAD2; TBR-ii; TBRll; TGFbeta-Rll; TGFR-2 |
| Host Species | Rabbit |
| Description | Biotinylated Anti-TGFBR2 antibody(DMC467); IgG1 Chimeric mAb |
| Delivery | 2-3 weeks |
| Uniprot ID | P37173 |
| IgG type | Rabbit/Human Fc chimeric IgG1 |
| Clonality | Monoclonal |
| Reactivity | Human |
| Applications | Flow Cyt |
| Recommended Dilutions | Flow Cyt 1:100 |
| Purification | Purified from cell culture supernatant by affinity chromatography |
| Formulation & Reconstitution | Lyophilized from sterile PBS, pH 7.4. Normally 5 % - 8% trehalose is added as protectants before lyophilization. Please see Certificate of Analysis for specific instructions of reconstitution. |
| Storage & Shipping | Store at -20°C to -80°C for 12 months in lyophilized form. After reconstitution, if not intended for use within a month, aliquot and store at -80°C (Avoid repeated freezing and thawing). Lyophilized proteins are shipped at ambient temperature. |
| Background | The protein encoded by this gene is a transmembrane protein that has a protein kinase domain; forms a heterodimeric complex with TGF-beta receptor type-1; and binds TGF-beta. This receptor:ligand complex phosphorylates proteins; which then enter the nucleus and regulate the transcription of genes related to cell proliferation; cell cycle arrest; wound healing; immunosuppression; and tumorigenesis. Mutations in this gene have been associated with Marfan Syndrome; Loeys-Deitz Aortic Aneurysm Syndrome; and the development of various types of tumors. Alternatively spliced transcript variants encoding different isoforms have been characterized. [provided by RefSeq; Aug 2017] |
| Usage | Research use only |
| Conjugate | Biotinylated |
| DIMA Disclaimer | All DIMA recombinant antibodies are genuinely generated by DIMA Biotech. They are all under patent application. Any protein sequencing or reverse engineering attempt is prohibited. We are actively scrutinizing all patent application to ensure no IP infringement. |

